Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception
下一代多用途预防技术:用于艾滋病毒预防和非激素避孕的阴道环
基本信息
- 批准号:10588268
- 负责人:
- 金额:$ 74.67万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-05 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:AIDS preventionAdherenceAffinityAfricanAgglutinationAnimal ModelAnti-Retroviral AgentsAntibodiesAntigen TargetingAutomobile DrivingBehavior monitoringBiological AssayBiologyBlocking AntibodiesCellsChemistryClinicalClinical TrialsCollaborationsComplementContraceptive AgentsContraceptive methodsDataDevelopmentDoseDrug CombinationsDrug Delivery SystemsDrug KineticsDrug StabilityEngineeringEpidemicFamily PlanningFutureGoalsHIVHIV InfectionsHormonesHourHumanHybridsImmunoglobulin GIn VitroIndividualInfectionKineticsKnowledgeLeadMacacaMacaca nemestrinaMeasuresMethodsModelingMonitorMonoclonal AntibodiesMucous body substanceOralPersonsPharmaceutical PreparationsPharmacologyPre-Clinical ModelPregnancyPreparationPreventionProcessPropertyPublic HealthRegimenResearchResearch PersonnelRiskSafetySheepSperm AgglutinationSwimmingTechnologyTemperatureTemperature SenseVaginaVaginal RingWomanYeastsarmbiocompatible polymerclinical efficacycontraceptive efficacycostcost effectivedesigneggfabricationglobal healthhealth organizationhuman malein vivoinfection rateinnovationinterestlead candidatemultiple omicsnanomolarnext generationnonhuman primatenovelpharmacokinetics and pharmacodynamicspre-clinicalpre-exposure prophylaxispreventprototypereproductive tractresponsesafety assessmentsexsimian human immunodeficiency virussmall moleculesperm cellsuccesstransmission processunintended pregnancyuptakevaginal microbiome
项目摘要
ABSTRACT
New HIV infection rates far outpace the targets set by global health organizations, despite important progress
in curbing the progression of the epidemic. In 2017, an estimated 1.8 million people became newly HIV
infected globally. New HIV pre-exposure prophylaxis (PrEP) strategies are needed urgently to curb this
alarming situation, particularly in young sub-Saharan African women who are disproportionately at risk. A high
proportion of women at risk of becoming HIV-infected also are interested in family planning, suggesting that a
dual-purpose product providing HIV prevention and contraception would significantly increase the likelihood of
higher uptake relative to single-purpose products, since unsurprisingly, women do not self-identify as being at
risk of HIV, but do so identify for pregnancy. Many women are averse to exogenous hormones and would
strongly prefer a nonhormonal method, and one that does not require use immediately before or after sex. Our
application integrates two leading innovations in developing a next generation multi-purpose technology (MPT)
intravaginal ring (IVR): (1) developing a novel, nonhormonal contraceptive agent based on a multivalent
monoclonal antibody (mAb) that blocks sperm from swimming through mucus and accessing the egg; and (2)
formulating the mAb contraceptive with antiretroviral (ARV) agents with demonstrated clinical efficacy in
preventing HIV in a behavior-monitoring IVR. We have recently engineered a unique IgG-based multivalent
mAb with 10 Fab arms against CD52g, a validated antigen target for contraception that is found only on cells in
the human male genital tract. This molecule, even at sub-nanomolar concentrations, effectively agglutinates
>99% of sperm within seconds, thus offering potentially potent yet cost-effective contraception. To complement
this novel agent, our team has developed an innovative IVR platform that delivers drug combinations including
small molecule drugs and mAbs. A low-cost module has been incorporated into the IVR to monitor temperature
as a surrogate measure of adherence. The MPT IVR will be formulated to provide long-term (30 days) dual
protection while evaluating adherence. In Aim 1, we will further enhance the mAb constructs against CD52g
through affinity maturation of anti-CD52g Fab using yeast-display, incorporate the optimized Fab into similar
multimeric mAb formats, and characterize their sperm agglutination potencies rigorously. In Aim 2, we will
formulate and evaluate in vitro human- and macaque-sized MPT IVRs to deliver our lead contraceptive mAb
candidate in combination with ARV drugs at target in vitro rates based on existing in vivo PK-PD data. We will
optimize and expand the adherence IVR design and evaluate prototypes in sheep. In Aim 3, we will assess the
pharmacokinetics and pharmacodynamics (safety and efficacy) of MPT IVR candidates in sheep and pigtailed
macaques. This project builds on an established collaboration of investigators and will advance our scientific
knowledge on the properties of sustained-release vaginal drug delivery in the context of HIV prevention and
contraception.
摘要
尽管取得了重要进展,但新的艾滋病毒感染率远远超过全球卫生组织设定的目标
在遏制疫情发展方面的作用。2017年,估计有180万人成为新的艾滋病毒感染者。
感染全球。迫切需要新的艾滋病毒暴露前预防(PrEP)策略来遏制这种情况
令人震惊的情况,特别是撒哈拉以南非洲的年轻妇女,她们面临的风险尤其大。高
有可能感染艾滋病毒的妇女中也有一部分对计划生育感兴趣,这表明,
提供艾滋病毒预防和避孕的两用产品将大大增加
与单一用途产品相比,女性的使用率更高,因为不出所料,女性并不认为自己处于
艾滋病毒的风险,但这样做确定怀孕。许多女性不喜欢外源性激素,
强烈偏好非荷尔蒙方法,且不需要在性交前后立即使用。我们
该应用程序集成了开发下一代多用途技术(MPT)的两项领先创新
阴道环(IVR):(1)开发一种基于多价
单克隆抗体(mAb),阻止精子游过粘液并接近卵子;和(2)
用抗逆转录病毒(ARV)药物配制mAb避孕药,
在行为监测IVR中预防艾滋病。我们最近设计了一种独特的IgG多价
具有10个针对CD 52 g的Fab臂的mAb,CD 52 g是一种经验证的避孕抗原靶点,仅存在于
人类男性的生殖道这种分子,即使在亚纳摩尔浓度下,
>99%的精子在几秒钟内,从而提供潜在的有效但具有成本效益的避孕。以补充
我们的团队开发了一种创新的IVR平台,可以提供药物组合,包括
小分子药物和mAb。一个低成本的模块已纳入IVR监测温度
作为一种替代的依从性测量。MPT IVR将被制定为提供长期(30天)双重
保护,同时评估遵守情况。在目标1中,我们将进一步增强针对CD 52 g的mAb构建体,
通过使用酵母展示的抗CD 52 g Fab的亲和力成熟,将优化的Fab掺入类似的
多聚体mAb形式,并严格表征其精子凝集效力。在目标2中,我们将
制定和评估体外人类和猕猴大小的MPT IVR,以提供我们的领先避孕mAb
基于现有的体内PK-PD数据,以目标体外速率与ARV药物组合的候选药物。我们将
优化和扩展依从性IVR设计,并在绵羊中评估原型。在目标3中,我们将评估
MPT IVR候选药物在绵羊和猪尾中的药代动力学和药效学(安全性和有效性)
猕猴该项目建立在研究人员的既定合作基础上,将推动我们的科学研究。
在预防艾滋病毒方面,了解阴道缓释药物输送的特性,
避孕。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Marc Michael Baum其他文献
Marc Michael Baum的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Marc Michael Baum', 18)}}的其他基金
Sustained Release of Potent Antiviral Prodrugs for HIV Prevention
持续释放有效的抗病毒前药以预防艾滋病毒
- 批准号:
10617540 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Systemic Sustained Release Delivery of Antiretroviral Agents for HIV Prevention
用于预防艾滋病毒的抗逆转录病毒药物的全身缓释递送
- 批准号:
10449318 - 财政年份:2021
- 资助金额:
$ 74.67万 - 项目类别:
Systemic Sustained Release Delivery of Antiretroviral Agents for HIV Prevention
抗逆转录病毒药物的全身缓释递送用于预防艾滋病毒
- 批准号:
10327138 - 财政年份:2021
- 资助金额:
$ 74.67万 - 项目类别:
Systemic Sustained Release Delivery of Antiretroviral Agents for HIV Prevention
用于预防艾滋病毒的抗逆转录病毒药物的全身缓释递送
- 批准号:
10654774 - 财政年份:2021
- 资助金额:
$ 74.67万 - 项目类别:
Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception
下一代多用途预防技术:用于艾滋病毒预防和非激素避孕的阴道环
- 批准号:
10158504 - 财政年份:2020
- 资助金额:
$ 74.67万 - 项目类别:
Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception
下一代多用途预防技术:用于艾滋病毒预防和非激素避孕的阴道环
- 批准号:
9926590 - 财政年份:2020
- 资助金额:
$ 74.67万 - 项目类别:
Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal Contraception
下一代多用途预防技术:用于艾滋病毒预防和非激素避孕的阴道环
- 批准号:
10359111 - 财政年份:2020
- 资助金额:
$ 74.67万 - 项目类别:
Systemic Sustained Release Delivery of Antiretroviral Agents for HIV Prevention
抗逆转录病毒药物的全身缓释递送用于预防艾滋病毒
- 批准号:
9089920 - 财政年份:2015
- 资助金额:
$ 74.67万 - 项目类别:
Systemic Sustained Release Delivery of Antiretroviral Agents for HIV Prevention
抗逆转录病毒药物的全身缓释递送用于预防艾滋病毒
- 批准号:
9277368 - 财政年份:2015
- 资助金额:
$ 74.67万 - 项目类别:
相似海外基金
I-Corps: Medication Adherence System
I-Corps:药物依从性系统
- 批准号:
2325465 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Standard Grant
Improving Repositioning Adherence in Home Care: Supporting Pressure Injury Care and Prevention
提高家庭护理中的重新定位依从性:支持压力损伤护理和预防
- 批准号:
490105 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Operating Grants
An innovative, AI-driven prehabilitation platform that increases adherence, enhances post-treatment outcomes by at least 50%, and provides cost savings of 95%.
%20创新、%20AI驱动%20康复%20平台%20%20增加%20依从性、%20增强%20治疗后%20结果%20by%20at%20至少%2050%、%20和%20提供%20成本%20节省%20of%2095%
- 批准号:
10057526 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Grant for R&D
CO-LEADER: Intervention to Improve Patient-Provider Communication and Medication Adherence among Patients with Systemic Lupus Erythematosus
共同领导者:改善系统性红斑狼疮患者的医患沟通和药物依从性的干预措施
- 批准号:
10772887 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Nuestro Sueno: Cultural Adaptation of a Couples Intervention to Improve PAP Adherence and Sleep Health Among Latino Couples with Implications for Alzheimer’s Disease Risk
Nuestro Sueno:夫妻干预措施的文化适应,以改善拉丁裔夫妇的 PAP 依从性和睡眠健康,对阿尔茨海默病风险产生影响
- 批准号:
10766947 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
- 批准号:
10594350 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Unintrusive Pediatric Logging Orthotic Adherence Device: UPLOAD
非侵入式儿科记录矫形器粘附装置:上传
- 批准号:
10821172 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Antiretroviral therapy adherence and exploratory proteomics in virally suppressed people with HIV and stroke
病毒抑制的艾滋病毒和中风患者的抗逆转录病毒治疗依从性和探索性蛋白质组学
- 批准号:
10748465 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Improving medication adherence and disease control for patients with multimorbidity: the role of price transparency tools
提高多病患者的药物依从性和疾病控制:价格透明度工具的作用
- 批准号:
10591441 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Development and implementation of peer-facilitated decision-making and referral support to increase uptake and adherence to HIV pre-exposure prophylaxis in African Caribbean and Black communities in Ontario
制定和实施同行协助决策和转介支持,以提高非洲加勒比地区和安大略省黑人社区对艾滋病毒暴露前预防的接受和依从性
- 批准号:
491109 - 财政年份:2023
- 资助金额:
$ 74.67万 - 项目类别:
Fellowship Programs